Global Heparin Market 2016-2020

2016-03-17
Price :
Published : Mar-2016
No. of Pages : 73

Heparin, a disaccharide anticoagulant or blood thinner, prevents the formation of blood clots. It is produced in the body by basophils and mast cells. It is stored within mast cells and secreted at the injury site. Though it has no effect on already formed clots, it enables the body’s natural clot lysis mechanisms to dissolve clots. It can also be taken from outside as a drug. Heparin can be derived from natural sources such as pig intestine and bovine lungs.

Heparin is divided into two types based on the fractionation process. Both types have medical use, with the selection done based on preference for a particular condition.

  • UFH: It is directly obtained from natural sources, without undergoing any fractionation.
  • LMWH: It is derived by depolymerizing UFH. The pharmacodynamics properties of LMWH are more predictable when compared to UFH.

Apart from these, another category of molecules, ULMWH are available. They are structurally related to LMWHs, but differ in the composition of monosaccharides and oligosaccharides. Therefore, they have different average molecular weights from LMWH.

The analysts forecast global heparin market to grow at a CAGR of 4.74% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global heparin market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generics used to treat disorders.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

The report, Global Heparin Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • GlaxoSmithKline plc (GSK)
  • Leo Pharma A/S
  • Pfizer Inc.
  • Sanofi

Other prominent vendors

  • Alchemi
  • Baxter
  • BMS
  • Boehringer Ingelheim
  • Celgene
  • Cosmo Pharmaceuticals
  • Dr.Reddy’s Laboratories
  • Eisai
  • Fresenius
  • GSK
  • Hospira
  • Laboratorios Rovi Pharmaceuticals
  • Lee’s Pharmaceutical
  • Momenta Pharmaceuticals
  • Mylan
  • Novartis
  • Ockham Biotech
  • Perospher
  • PolyMedix
  • Portola Pharmaceutical
  • ProStrakan Group
  • Sagent Pharmaceticals
  • Sigma Tau Pharmaceuticals
  • UCB
  • Urigen Pharmaceuticals

Market driver

  • Growing prevalence of diseases
  • For a full, detailed list, view our report

Market challenge

  • Extensive use of generic products due to patent expirations
  • For a full, detailed list, view our report

Market trend

  • Expected exploitation of new therapeutic use
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?
Filed in: Pharmaceutical
Publisher : Technavio
More Reports
Title Price Buy Now

EpiCast Report: Alzheimer’s Disease – Epidemiology Forecast to 2026

EpiCast Report: Alzheimer's Disease - Epidemiology Forecast to 2026 Summary Alzheimer's disease (AD) is a subtype of dementia and is an irreversible, neurodegenerative brain disease of the elderly, characterized by the death of brain cells, which leads to a progressive decline in memory and cognitive abilities, such as thinking, language, and learning capacity (NIA, 2017). AD is the most common cause of dementia in people age 60 years and older, and accounts for approximately 75% of the total dementia cases worldwide. To forecast the total prevalent cases of AD in adults ages 60 years and older in the 7MM during the forecast period (2016-2026), our epidemiologists identified country-specific population-based studies that used the diagnostic criteria based on the Diagnostic and Sta......
$3995

EpiCast Report: Epilepsy – Epidemiology Forecast to 2026

EpiCast Report: Epilepsy - Epidemiology Forecast to 2026 Summary Epilepsy is a brain disorder characterized by recurrent and unpredictable seizures that are caused by sudden, disorderly, and excessive neuronal activity in the brain (WHO, 2017). It is one of the most common neurological conditions globally (WHO, 2017). Epilepsy can start at any age and can be a life-long condition. It is diagnosed after a patient has suffered a seizure and is referred to a specialist, where a description of the symptoms before the seizure and the seizure itself are used for a diagnosis (NHS, 2014). In the 7MM, the lifetime diagnosed prevalent cases of epilepsy will increase from almost 11 million cases in 2016 to just over 11.5 million cases in 2026, at an Annual Growth Rate (AGR) of almost 0.5% pe......
$3995

Partnerships, Licensing, Investments and M&A Deals and Trends for August 2017 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for August 2017 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for August 2017 in Pharmaceuticals", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in August 2017. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report p......
$1000

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Argentina

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Argentina Summary Pharmaceutical market increased from over US$3 Billion in 2009 to around US$6.5 Billion in 2016, at a Compound Annual Growth Rate (CAGR) of nearly 10%. It is expected to cross US$10 Billion in 2021 at a CAGR of about 10%. In 2009, the medical device market was valued at just over US$1 Billion. It grew at a CAGR of 4% between 2009 and 2016 and reached around US$1.3 Billion. It is expected to grow at a CAGR of about 5%, from around US$1.4 Billion in 2017 to over US$1.7 Billion in 2021. Argentina is the third-largest pharmaceutical market in Latin America after Brazil and Mexico. With a relatively low-cost base and high-quality professionals in the biotechnology sector, Argentina is home to over 130 ......
$1995

EpiCast Report: Melanoma – Epidemiology Forecast to 2026

EpiCast Report: Melanoma - Epidemiology Forecast to 2026 Summary Melanoma is a malignant neoplasm of melanocytes, the pigment cells in the skin located on the epidermis, the most superficial layer of skin (WHO, 2014). Melanocytes are embryological derivatives of neural crest tissue, and as such, any region of the body that is a derivative of the neural crest and contains melanocytes-namely areas of skin, meninges, mucous membranes, esophagus, and eyes-can develop melanoma (Komarnicky-Kocher and Alite, 2013). In the 7MM, our epidemiologists forecast the diagnosed incident cases of melanoma to increase to over 200,000 cases by 2026, at an Annual Growth Rate (AGR) of almost 2.5%. The US will have the highest number of melanoma cases throughout the forecast period. The five-year diagn......
$3995

EpiCast Report: Crohn’s Disease – Epidemiology Forecast to 2026

EpiCast Report: Crohn's Disease - Epidemiology Forecast to 2026 Summary Crohn's disease (CD) is an inflammatory bowel disease (IBD) characterized by chronic inflammation of the gastrointestinal tract. While any part of the gastrointestinal tract can be affected, inflammation is most commonly found at the end of the small intestine (ileum), and the start of the large intestine (colon). The disease course of CD is characterized by periods of remission followed by periods of relapse, the length and severity of which differ from case to case (CDC, 2014; NHS, 2015). Inflammation in CD can result in severe scarring and narrowing of the parts of the bowel. Our epidemiologists forecast that the diagnosed incident cases of CD in the 7MM will increase from 70,985 in 2016 to 74,712 in 2026 a......
$3995

Hyperkalemia Global Clinical Trials Review, H2, 2017

Hyperkalemia Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hyperkalemia Global Clinical Trials Review, H2, 2017" provides an overview of Hyperkalemia clinical trials scenario. This report provides top line data relating to the clinical trials on Hyperkalemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical......
$2500

Hyperalgesia Global Clinical Trials Review, H2, 2017

Hyperalgesia Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hyperalgesia Global Clinical Trials Review, H2, 2017" provides an overview of Hyperalgesia clinical trials scenario. This report provides top line data relating to the clinical trials on Hyperalgesia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical......
$2500

Hyperlipidemia Global Clinical Trials Review, H2, 2017

Hyperlipidemia Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hyperlipidemia Global Clinical Trials Review, H2, 2017" provides an overview of Hyperlipidemia clinical trials scenario. This report provides top line data relating to the clinical trials on Hyperlipidemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. ......
$2500

Hyperammonemia Global Clinical Trials Review, H2, 2017

Hyperammonemia Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hyperammonemia Global Clinical Trials Review, H2, 2017" provides an overview of Hyperammonemia clinical trials scenario. This report provides top line data relating to the clinical trials on Hyperammonemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. ......
$2500